Global trends of antimicrobial susceptibility of ceftaroline and ceftazidime-avibactam: a surveillance study from the ATLAS program (2012-2016)

Zhang, Hui; Xu, Yingchun; Jia, Peng; Zhu, Ying; Zhang, Ge; Zhang, Jingjia; Duan, Simeng; Kang, Wei; Wang, Tong; Jing, Ran; Cheng, Jingwei; Liu, Yali; Yang, Qiliang

doi:10.21203/rs.3.rs-31962/v3

Cited by 4 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study reported susceptibility of CR-E. coli to be 72.3% using Clinical Laboratory and Standards Institute (CLSI) breakpoints against ceftazidime-avibactam. Similarly, susceptibility of CR-K. pneumoniae was reported to be 85.6% using CLSI breakpoints [18].…”

Section: In Vitro Activitymentioning

confidence: 98%

Early and Appropriate Use of Ceftazidime-Avibactam in the Management of Multidrug-Resistant Gram-Negative Bacterial Infections in the Indian Scenario

Swaminathan¹,

Routray²,

Mane³

2022

Cureus

View full text Add to dashboard Cite

The increasing prevalence of antibiotic-resistant pathogens exerts a substantial burden on the healthcare infrastructure worldwide. The World Health Organization (WHO) has declared that multidrug-resistant (MDR) Gram-negative pathogens, especially, carbapenem-resistant Enterobacterales (CRE), Acinetobacter baumannii, and Pseudomonas aeruginosa as the topmost priority while developing newer antimicrobials. The increasing prevalence of infectious diseases caused by MDR Gram-negative bacteria also poses a challenge when choosing the empiric antimicrobial therapy for seriously ill hospitalized patients. The infections caused by MDR Gram-negative organisms ultimately result in increased mortality, morbidity, prolonged hospital stay, and increased cost of management. To tackle these challenges, newer antimicrobials like ceftazidime-avibactam were explored. The article also discusses the in vitro activity and therapeutic efficacy of ceftazidime-avibactam along with its pharmacokinetic properties and the role it will play in the management of MDR Gram-negative organisms in the Indian setting. Several studies have highlighted the role of early and appropriate antibiotic use in the reduction of mortality in patients with Gram-negative infections. Timely initiation of appropriate antibiotic therapy for serious infections leads to favorable clinical outcomes. Early and appropriate use of ceftazidime-avibactam while treating MDR Gram-negative infections has been associated with improved clinical outcomes. The aim of this review is to highlight the efficacy of ceftazidime-avibactam in the treatment of MDR Gram-negative infections. We have also summarized the information on outcomes achieved by early and appropriate use of ceftazidime-avibactam.

show abstract

Section: In Vitro Activitymentioning

confidence: 98%

Early and Appropriate Use of Ceftazidime-Avibactam in the Management of Multidrug-Resistant Gram-Negative Bacterial Infections in the Indian Scenario

Swaminathan¹,

Routray²,

Mane³

2022

Cureus

View full text Add to dashboard Cite

show abstract

“…aeruginosa producing different carbapenemases: among Enterobacteriaceae , KPC‐producing strains were resistant to CAZ/AVI at 1.5%, and NDM‐producing strains at 99.6%, while among P . aeruginosa , KPC‐producing strains were resistant to CAZ/AVI at 35.7% and NDM‐producing strains at 97% (Table 1; Kiratisin et al, 2021; H. Zhang, Xu, et al, 2020).…”

Section: Prevalence Of Caz/avi‐resistant Bacteriamentioning

confidence: 99%

“…By 2017–2019, carbapenem nonsusceptible Enterobacteriaceae bacteria in Latin America increased their resistance rate to CAZ/AVI nearly 1‐fold to 25.3% (Karlowsky et al, 2021). In addition, global resistance surveillance by the ATLAS project from 2012 to 2016 showed that carbapenem‐resistant Enterobacteriaceae had a resistance rate of 57.7% to CAZ/AVI, followed by CREC with a resistance rate of 27.7% to CAZ/AVI (H. Zhang, Xu, et al, 2020). The distribution of resistance rate of CRE to CAZ/AVI in different regions was as follows: the highest resistance rate to CAZ/AVI was 66.6% in the Asia‐Pacific region, followed by Africa‐Middle East (39.5%), Europe (28.0%), and Latin America (18.5%), whose trend was consistent with the 2015–2017 INFORM surveillance system showing the distribution of resistance rates of carbapenem nonsusceptible Enterobacteriaceae to CAZ/AVI (Table 1).…”

Section: Prevalence Of Caz/avi‐resistant Bacteriamentioning

confidence: 99%

Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam

Xiong

Wang

et al. 2022

WIREs Mechanisms of Disease

View full text Add to dashboard Cite

Ceftazidime/avibactam (CAZ/AVI), a combination of ceftazidime and a novel β-lactamase inhibitor (avibactam) that has been approved by the U.S. Food and Drug Administration, the European Union, and the National Regulatory Administration in China. CAZ/AVI is used mainly to treat complicated urinary tract infections and complicated intra-abdominal infections in adults, as well as to treat patients infected with Carbapenem-resistant Enterobacteriaceae (CRE) susceptible to CAZ/AVI. However, increased clinical application of CAZ/AVI has resulted in the development of resistant strains. Mechanisms of resistance in most of these strains have been attributed to bla KPC mutations, which lead to amino acid substitutions in β-lactamase and changes in gene expression. Resistance to CAZ/AVI is also associated with reduced expression and loss of outer membrane proteins or overexpression of efflux pumps. In this review, the prevalence of CAZ/AVI-resistance bacteria, resistance mechanisms, and selection of detection methods of CAZ/AVI are demonstrated, aiming to provide scientific evidence for the clinical prevention and treatment of CAZ/AVI resistant strains, and provide guidance for the development of new drugs.

show abstract

“…11,12 This fifth-generation broad spectrum cephalosporin possesses activity against common Gram-positive pathogens found in bacterial skin and skin structure infections and community-acquired pneumonia, including MRSA. 13,14 Additionally, ceftaroline demonstrates activity against respiratory tract Gram-negative pathogens, including Moraxella catarrhalis, Haemophilus parainfluenzae and H. influenzae , along with other enteric bacilli. 15 Efficacy against β-lactam–resistant S. aureus can be explained by the high affinity of ceftaroline for staphylococcal PBPs 1, 2 and 3 and MRSA PBP2a.…”

Section: Introductionmentioning

confidence: 99%

In vitro Activity of Ceftaroline Against an International Collection of Kingella kingae Isolates Recovered From Carriers and Invasive Infections

Maher

Mendes

Huynh

et al. 2022

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

Background: Improvements in blood culture techniques and molecular-based diagnostics have led to increased recognition of Kingella kingae as an invasive human pathogen causing bacteremia, septic arthritis, osteomyelitis and endocarditis in young children. Serious disease and potentially life-threatening complications of infection due to K. kingae necessitate timely identification and appropriate antimicrobial therapy. Ceftaroline is a fifth-generation broad spectrum cephalosporin that possesses activity against Gram-negative and Gram-positive pathogens similar to third-generation cephalosporins, but also includes methicillin-resistant Staphylococcus aureus. This study reports the in vitro activity of ceftaroline and comparator agents against an international collection of K. kingae isolates. Methods: A collection of 308 K. kingae isolates was obtained primarily from children with bacteremia, endocarditis, osteoarticular infections or from asymptomatic pediatric carriers. Isolates were tested for antibiotic susceptibility using Clinical and Laboratory Standard Institute broth microdilution methodology and screened for β-lactamase production using a nitrocefin chromogenic test. Results: Ceftaroline inhibited all K. kingae isolates at ≤0.06 mg/L (MIC50/90, 0.015/0.03 mg/L). Ceftaroline MICs were similar to results with ceftriaxone (MIC50/90, 0.015/0.015 mg/L), meropenem (MIC50/90, 0.015/0.015 mg/L) and ampicillin–sulbactam (MIC50/90, 0.06/0.06 mg/L). Ceftaroline MICs were slightly lower than MICs for cefuroxime and amoxicillin/clavulanate (MIC50/90, 0.06/0.12 mg/L). MICs were high for clindamycin (MIC50/90, 2/4 mg/L) and oxacillin (MIC50/90, 4/8 mg/L). Sixteen isolates (5.2%) yielded a positive nitrocefin test indicating production of β-lactamase; ceftaroline demonstrated equivalent MICs against β-lactamase–positive and β-lactamase–negative strains (MIC50/90, 0.015/0.3 mg/L). Conclusions: The potent activity of ceftaroline against this large international collection of K. kingae isolates supports further clinical evaluation in children.

show abstract

Global trends of antimicrobial susceptibility of ceftaroline and ceftazidime-avibactam: a surveillance study from the ATLAS program (2012-2016)

Cited by 4 publications

References 28 publications

Early and Appropriate Use of Ceftazidime-Avibactam in the Management of Multidrug-Resistant Gram-Negative Bacterial Infections in the Indian Scenario

Early and Appropriate Use of Ceftazidime-Avibactam in the Management of Multidrug-Resistant Gram-Negative Bacterial Infections in the Indian Scenario

Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam

In vitro Activity of Ceftaroline Against an International Collection of Kingella kingae Isolates Recovered From Carriers and Invasive Infections

Contact Info

Product

Resources

About